These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Kim JH, Kim D, Marder SR. Prog Neuropsychopharmacol Biol Psychiatry; 2008 May 15; 32(4):984-8. PubMed ID: 18262321 [Abstract] [Full Text] [Related]
14. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. Novick D, Haro JM, Bertsch J, Haddad PM. J Clin Psychopharmacol; 2010 Oct 15; 30(5):531-40. PubMed ID: 20814320 [Abstract] [Full Text] [Related]
15. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. Chengappa KN, Sheth S, Brar JS, Parepally H, Marcus S, Gopalani A, Palmer A, Baker RW, Schooler NR. J Clin Psychiatry; 1999 Jun 15; 60(6):373-8. PubMed ID: 10401915 [Abstract] [Full Text] [Related]
18. Rehospitalization risk with second-generation and depot antipsychotics. Conley RR, Kelly DL, Love RC, McMahon RP. Ann Clin Psychiatry; 2003 Mar 15; 15(1):23-31. PubMed ID: 12839430 [Abstract] [Full Text] [Related]
20. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. Clin Ther; 2010 Jan 15; 32(1):108-18. PubMed ID: 20171417 [Abstract] [Full Text] [Related] Page: [Next] [New Search]